In this study, the authors first used an AlphaScreen assay to identify a series of tryptophan-based cyclic peptide compounds with FXR-antagonistic activity, specifically those modified with a ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic ...
AZoLifeSciences on MSN2d
Study Explores the Physiological Role of Nwd1 Gene in MASH PathogenesisMetabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder influenced by multiple genes, but their ...
MASH is marked by lipid droplet accumulation ... potentially leading to novel strategies to combat this growing public health issue," concludes Dr. Yamada.
News Medical on MSN4d
Gene Deletion Sparks MASH Pathology in Mice BreakthroughMetabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated ...
Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the ... of the Chinese Academy of Sciences identified a novel mechanism in understanding the therapeutic mechanism ...
The MASH landscape has changed dramatically since ... late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases.
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ... dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback